Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Multiple Myeloma 70Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Mantle-Cell 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Myeloid, Acute 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Non-Hodgkin 12Recurrence 11Neoplasms, Plasma Cell 10Lymphoma 10Myelodysplastic Syndromes 9Hodgkin Disease 8Neoplasms 7Leukemia 7Burkitt Lymphoma 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Immunoblastic 4Astrocytoma 4Smoldering Multiple Myeloma 3Prostatic Neoplasms 3Oligodendroglioma 3Melanoma 3

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × Lenalidomide × Clear all
NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡